Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01509079 · ClinicalTrials.gov registry record · Phase 2
Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors
A Phase 2 study, sponsored by HealthPartners Institute.
- Completed
- Registry status
- Phase 2
- Development phase
- 116
- Enrollment target
NCT01509079: Completed Phase 2 study, sponsored by HealthPartners Institute.
NCT01509079 is a Phase 2 study that has completed, run by HealthPartners Institute. The registered enrollment target is 116 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01509079, a Phase 2 study, has completed, sponsored by HealthPartners Institute.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 116 participants
- Enrollment target
Study Summary
The Purpose of this study is to determine whether vitamin D3 supplements will decrease the muscle and bone pain that are reported by women who take Aromatase Inhibitors.
Primary Outcome
The MS subscale is a self-reported measure on a scale of 0 to 4, with lower score indicating less arthralgia/myalgia
Interventions
- DRUG Vitamin D3
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 116 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-03 |
| Phase | Phase 2 |
What the finished NCT01509079 record still lists
NCT01509079 is an interventional study that assigns participants to a tested intervention. The registered 116 participants enrollment target is mid-sized for trials with a published cap, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (13% lower).
The record links to 0 conditions, and to 1 intervention - of which Vitamin D3 is the first listed.
NCT01509079 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01509079 about?
NCT01509079 is a clinical study titled "Vitamin D3 Effects on Musculoskeletal Symptoms With Use of Aromatase Inhibitors". The Purpose of this study is to determine whether vitamin D3 supplements will decrease the muscle and bone pain that are reported by women who take Aromatase Inhibitors.
What is the current status of trial NCT01509079?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 116 participants. The study started on 2012-03. Estimated completion is 2015-03.
What interventions are being tested in trial NCT01509079?
The interventions under investigation include: Vitamin D3 (DRUG).
Who is sponsoring clinical trial NCT01509079?
This trial is sponsored by HealthPartners Institute, which has 146 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01509079's enrollment target sits among peer trials
116 623rd of 2000 higher than 1,375 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03014687 · 116 participants · Phase 4
Prophylactic Oral Antibiotics on Sinonasal Outcomes Following Endoscopic Transsphenoidal Surgery for Pituitary Lesions
- NCT03214562 · 116 participants · Phase 1
Venetoclax With Combination Chemotherapy in Treating Patients With Newly Diagnosed or Relapsed or Refractory Acute Myeloid Leukemia
- NCT03847467 · 116 participants · Phase 1
Pilot and Feasibility Study of 2'-FL as a Dietary Supplement in IBD Patients Receiving Stable Maintenance Anti-TNF Therapy
- NCT04222413 · 116 participants · Phase 1
Metarrestin (ML-246) in Subjects With Metastatic Solid Tumors
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia